g u i d e l i n e s u m m a r y Kidney International (2018) 94, 663-673 Algorithm 1 | Treatment scheme for chronic kidney disease (CKD) G1 to G5D. (See Algorithm 2 for kidney transplant recipients.) Recommendation grades (1À2) and strength of evidence (AÀD) are provided for each recommended treatment regimen and hepatitis C virus (HCV) genotype; see full guideline. 1 DAA, direct-acting antiviral; GFR, glomerular filtration rate; NAT, nucleic acid testing. M Jadoul et al.: Summary of 2018 KDIGO HCV in CKD Guideline g u i d e l i n e s u m m a r y Kidney International (2018) 94, 663-673 g u i d e l i n e s u m m a r y M Jadoul et al.: Summary of 2018 KDIGO HCV in CKD Guideline

No abstract

No abstract

No abstract

No abstract

Patients with F-AIH have a more indolent presentation compared with the non-F-AIH population. Altogether, only eight (20%) patients presenting with F-AIH survived without LT. A subset of patients with F-AIH and an initial MELD score less than 27 and low-grade hepatic encephalopathy might benefit from administration of corticosteroids.

No abstract

No abstract